Opthea's Phase 3 Trials for Wet AMD Treatment with Sozinibercept Complete Participant Enrollment

Opthea's Phase 3 Clinical Program Progresses:

Opthea has achieved a key milestone by completing the enrollment phase of its pivotal Phase 3 trials with Sozinibercept for the treatment of Wet AMD.

Significance for Wet AMD Treatment:

This advancement represents a critical step towards potentially introducing an innovative treatment option for individuals with Wet AMD, a prevalent eye condition.

Opthea's Phase 3 trials with Sozinibercept hold promise for addressing the unmet medical needs of patients suffering from Wet AMD.